Supporting Information

Palladium(0)-Catalyzed Direct C-H Hetero-Arylation of 2-arylimidazo[1,2-a]pyridines with (*E*)-1-(5-bromothiophen-2-yl)-3-arylprop-2-en-1-ones and Their Anticancer Activity

Mari Vellakkaran,^a Rajaka Lingayya,^{a,b} Bejjanki Naveen Kumar,^a Kommu Nagaiah,*a,b Y. Poornachandra,^c C. Ganesh Kumar^c

- ^a Organic and Biomolecular Chemistry Division, CSIR- Indian Institute of Chemical Technology, Tarnaka, Hyderabad, India-500007. E-mail:nagaiah@iict.res.in
- ^b Academy of Scientific and Innovative Research (AcSIR), CSIR Indian Institute of Chemical Technology, Hyderabad, India.
- ^c Medicinal Chemistry and Pharmacology Division, CSIR-Indian Institute of Chemical Technology, Uppal Road, Hyderabad 500 007, India.

Table of Contents

Serial No.	Description	Page No.
1.1	General Experimental	S2
1.2	General Experimental Procedure	S2
1.3	Analytical Data	S2-S11
1.4	References	S11
1.5	¹ H NMR and ¹³ C NMR Spectra	S12-S30

1.1 General Experimental Details:

All solvents and reagents were used, as received from the suppliers. TLC was performed on Merck Kiesel gel 60, F₂₅₄ plates with the layer thickness of 0.25 mm. Column chromatography was performed on silica gel (60-120 mesh) using a gradient of ethyl acetate and hexane as mobile phase. Melting points were determined on a Fisher John's melting point apparatus and are uncorrected. IR spectra were recorded on a Brucker Alpha Spectrometer FT-IR system. ¹H NMR spectral data were collected at 300 (AVANCE & JCAMP), 400 (INOVA) & 500 (INOVA & AVANCE) MHz, while ¹³C NMR were recorded at 75, 100 & 125 MHz. ¹H NMR spectral data are given as chemical shifts in ppm followed by multiplicity (s- singlet; d- doublet; t- triplet; q- quartet; m- multiplet), number of protons and coupling constants. ¹³C NMR chemical shifts are expressed in ppm. HRMS (ESI) spectral data were collected using ORBITRAP High Resolution Mass Spectrometer. Starting materials [2-arylimidazo[1,2-a]pyridines¹ and (*E*)-1-(5-bromothiophen-2-yl)-3-arylprop-2-en-1-ones²] were prepared as previously reported literatures.

1.2 General Procedure for Synthesis of (E)-3-aryl-1-(5-(2-arylimidazo[1,2-a]pyridin-3-yl)thiophen-2-yl)prop-2-en-1-one derivatives from 2-arylimidazo[1,2-a]pyridines:

A solution of 2-arylimidazo[1,2-a]pyridine (0.5 mmol) and Pd(OAc)₂ (0.025 equiv.), P(Cy)₃ (0.05 equiv.), K₂CO₃ (2.0 equiv.) and (*E*)-1-(5-bromothiophen-2-yl)-3-arylprop-2-en-1-ones (0.6 mmol) in DMA (4.0 mL) was taken in a 10.0 mL RB flask, which was then attached to N₂ atmosphere. The mixture was vigorously stirred at 90 °C for 18 h. The completion of reaction was monitored by TLC. After cooling to room temperature, the reaction mixture was partitioned between ethyl acetate (25.0 mL) and water (25.0 mL) in a separatory funnel. The organic layer was washed with water, and brine, dried over anhydrous Na₂SO₄ (s) and concentrated *in vacuo*. The residue was purified by column chromatography using a gradient of hexane and ethyl acetate (eluent system) to afford the pure product.

1.3 Analytical data for products

(E)-3-phenyl-1-(5-(2-phenylimidazo[1,2-a]pyridin-3-yl)thiophen-2-yl)prop-2-en-1-one (3a)

Following the general procedure, the residue was purified by column chromatography (silica gel 60-120 mesh, 15% ethyl acetate in hexane as the eluent) to afford the title product as a yellow solid (0.197 g, 97%). M.p. 130-131 °C; ¹H NMR (300

MHz, CDCl₃) δ 8.22 (d, J = 6.9 Hz, 1H), 7.92 (t, J = 9.9 Hz, 2H), 7.75 – 7.64 (m, 5H), 7.44 (dd, J = 8.9, 5.7 Hz, 4H), 7.37 – 7.23 (m, 5H), 6.88 (dd, J = 6.8, 0.8 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 181.6, 147.0, 145.9, 144.6, 138.5, 134.6, 133.4, 132.4, 130.8, 130.7, 129.0, 128.6, 128.5, 128.5, 128.3, 125.8, 123.8, 121.1, 117.8, 113.2; (IR, Neat): 3056, 1640,1435, 1220, 752, 697 cm⁻¹; HRMS (ESI): Calculated for [C₂₆H₁₉ON₂S]⁺ 407.12126; Found 407.11890.

(E)-3-(4-methoxyphenyl)-1-(5-(2-phenylimidazo[1,2-a]pyridin-3-yl)thiophen-2-yl)prop-2-en-1-one (3b)

Following the general procedure, the residue was purified by column chromatography (silica gel 60-120 mesh, 15% ethyl acetate in hexane as the eluent) to afford the title product as a yellow solid (0.190 g, 87%). M.p. 182-183 °C; ¹H NMR

(300 MHz, CDCl₃) δ 8.21 (d, J = 6.8 Hz, 1H), 7.90 (dd, J = 13.1, 9.7 Hz, 2H), 7.72 (d, J = 5.0 Hz, 3H), 7.62 (d, J = 8.4 Hz, 2H), 7.37 – 7.23 (m, 6H), 6.95 (d, J = 8.3 Hz, 2H), 6.87 (t, J = 6.7 Hz, 1H), 3.86 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 181.7, 161.9, 147.4, 145.8, 144.5, 138.1, 133.4, 132.1, 130.7, 130.5, 128.5, 128.4, 128.2, 127.3, 125.8, 123.8, 118.7, 117.7, 114.5, 113.2, 55.5; (IR, Neat): 2934, 1641, 1436, 1216, 749, 696 cm⁻¹; HRMS (ESI): Calculated for $[C_{27}H_{21}O_2SN_2]^+$ 437.13183; Found 437.12885.

(E)-3-(2,4-dimethoxyphenyl)-1-(5-(2-phenylimidazo[1,2-a]pyridin-3-yl)thiophen-2-yl)prop-2-en-1-one (3c)

Following the general procedure, the residue was purified by column chromatography (silica gel 60-120 mesh, 20% ethyl acetate in hexane as the eluent) to afford the title product as a yellow solid (0.217 g, 93%). M.p. 135-137 °C; ¹H NMR

(300 MHz, CDCl₃) δ 8.20 (d, J = 6.8 Hz, 1H), 8.12 (d, J = 15.6 Hz, 1H), 7.90 (d, J = 3.6 Hz, 1H), 7.72 (t, J = 6.7 Hz, 3H), 7.57 (d, J = 8.5 Hz, 1H), 7.48 (d, J = 15.6 Hz, 1H), 7.36 – 7.21 (m,

5H), 6.86 (t, J = 6.7 Hz, 1H), 6.56 – 6.47 (m, 2H), 3.91 (s, 3H), 3.85 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 182.3, 163.3, 160.7, 147.8, 145.8, 145.3, 140.4, 137.5, 133.5, 131.8, 131.5, 130.7, 128.5, 128.4, 128.2, 125.7, 123.8, 119.5, 117.7, 116.9, 113.3, 113.1, 105.6, 98.5, 55.6, 55.5; (IR, Neat): 2962, 1639, 1436, 1212, 735, 697 cm⁻¹; HRMS (ESI): Calculated for [C₂₈H₂₃O₃N₂S]⁺ 467.14239; Found 467.13904.

(E)-1-(5-(2-phenylimidazo[1,2-a]pyridin-3-yl)thiophen-2-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (3d)

Following the general procedure, the residue was purified by column chromatography (silica gel 60-120 mesh, 30% ethyl acetate in hexane as the eluent) to afford the title product as a yellow solid (0.228 g, 92%). M.p. 145-146 °C; ¹H NMR

(500 MHz, CDCl₃) δ 8.23 – 8.20 (m, 1H), 7.96 (d, J = 3.9 Hz, 1H), 7.82 (d, J = 15.5 Hz, 1H), 7.73 (dd, J = 5.2, 3.1 Hz, 3H), 7.38 – 7.30 (m, 5H), 7.25 (d, J = 3.9 Hz, 1H), 6.90 – 6.86 (m, 3H), 3.93 (s, 6H), 3.91 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 181.5, 153.5, 147.0, 145.8, 145.4, 144.8, 140.8, 138.3, 133.3, 132.4, 130.8, 130.0, 128.5, 128.5, 128.3, 126.0, 123.8, 120.4, 117.7, 113.3, 105.9, 61.1, 56.3; (IR, Neat): 2938, 1645, 1435, 1280, 753, 699 cm⁻¹; HRMS (ESI): Calculated for [C₂₉H₂₅O₄N₂S]⁺ 497.15295; Found 497.14944. Elemental Analysis: Calculated C, 70.14; H, 4.87; N, 5.64; S, 6.46; Found C, 69.83; H, 5.37; N, 3.97; S, 5.77.

(E)-3-(4-bromophenyl)-1-(5-(2-phenylimidazo[1,2-a]pyridin-3-yl)thiophen-2-yl)prop-2-en-1-one (3e)

Following the general procedure, the residue was purified by column chromatography (silica gel 60-120 mesh, 15% ethyl acetate in hexane as the eluent) to afford the title product as a yellow solid (0.208 g, 86%). M.p. 165-166 °C; ¹H NMR (400

MHz, CDCl₃) δ 8.23 (d, J = 6.9 Hz, 1H), 7.93 (d, J = 3.9 Hz, 1H), 7.83 (d, J = 15.6 Hz, 1H), 7.73


-7.70 (m, 2H), 7.58 - 7.51 (m, 5H), 7.42 (d, J = 15.6 Hz, 1H), 7.37 - 7.31 (m, 4H), 7.30 - 7.27 (m, 1H), 6.88 (td, J = 6.8, 1.1 Hz, 1H); 13 C NMR (100 MHz, CDCl₃) δ 181.3, 146.7, 145.9, 143.2, 138.8, 133.5, 133.4, 132.5, 132.3, 131.5, 130.7, 129.9, 128.7, 128.6, 128.5, 128.3, 125.8, 125.2, 123.8, 121.7, 117.8, 113.2; (IR, Neat): 2960, 1648, 1405, 1238, 751, 664 cm⁻¹; HRMS (ESI): Calculated for $[C_{26}H_{18}ON_2SBr]^+$ 485.03177; Found 485.02863.

(E)-4-(3-oxo-3-(5-(2-phenylimidazo[1,2-a]pyridin-3-yl)thiophen-2-yl)prop-1-en-1-yl)benzonitrile (3f)

Following the general procedure, the residue was purified by column chromatography (silica gel 60-120 mesh, 15% ethyl acetate in hexane as the eluent) to afford the title product as a yellow solid (0.174 g, 81%). M.p. 152-154 °C; ¹H NMR (300

MHz, CDCl₃) δ 8.24 (d, J = 6.9 Hz, 1H), 7.96 (d, J = 3.9 Hz, 1H), 7.87 (d, J = 15.6 Hz, 1H), 7.78 -7.68 (m, 5H), 7.50 (d, J = 15.6 Hz, 1H), 7.37 (dd, J = 11.0, 4.9 Hz, 5H), 7.23 -7.11 (m, 2H), 6.91 (t, J = 6.8 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 197.3, 146.0, 144.6, 141.9, 139.4, 132.9, 132.7, 132.5, 132.4, 130.7, 129.5, 128.8, 128.6, 128.5, 128.4, 128.3, 126.0, 124.2, 123.7, 118.4, 117.8, 113.6, 113.3; (IR, Neat): 3017, 2227, 1648, 1436, 1223,752, 696 cm⁻¹; HRMS (ESI): Calculated for $[C_{27}H_{18}ON_3S]^+$ 432.11651; Found 432.11343.

(E) - 1 - (5 - (2-phenylimidazo[1,2-a]pyridin-3-yl) thiophen-2-yl) - 3 - (p-tolyl) prop-2-en-1-one (3g)



Following the general procedure, the residue was purified by column chromatography (silica gel 60-120 mesh, 15% ethyl acetate in hexane as the eluent) to afford the title product as a yellow solid (0.199 g, 95%). M.p. 163-164 °C; ¹H NMR (500

MHz, CDCl₃) δ 8.21 (d, J = 6.7 Hz, 1H), 7.93 (d, J = 3.6 Hz, 1H), 7.88 (d, J = 15.5 Hz, 1H), 7.72 (t, J = 6.9 Hz, 3H), 7.56 (d, J = 7.8 Hz, 2H), 7.40 (d, J = 15.6 Hz, 1H), 7.37 – 7.22 (m, 7H), 6.87 (t, J = 6.6 Hz, 1H), 2.40 (s, 3H); 13 C NMR (75 MHz, CDCl₃) δ 181.7, 147.2, 145.8, 145.5, 144.7,


141.5, 138.3, 133.4, 132.3, 131.8, 130.7, 129.8, 128.6, 128.5, 128.4, 128.2, 125.8, 123.8, 120.1, 117.7, 113.2, 21.6; (IR, Neat): 2959, 1643, 1435, 1224, 749, 697 cm⁻¹; HRMS (ESI): Calculated for [C₂₇H₂₁ON₂S]⁺ 421.13691; Found 421.13416.

(E)-1-(5-(2-phenylimidazo[1,2-a]pyridin-3-yl)thiophen-2-yl)-3-(o-tolyl)prop-2-en-1-one (3h)

Following the general procedure, the residue was purified by column chromatography (silica gel 60-120 mesh, 15% ethyl acetate in hexane as the eluent) to afford the title product as a yellow solid (0.197 g, 94%). M.p. 173-174 °C; ¹H NMR (300

MHz, CDCl₃) δ 8.27 – 8.18 (m, 2H), 7.95 (d, J = 3.7 Hz, 1H), 7.72 (d, J = 6.5 Hz, 4H), 7.47 – 7.19 (m, 10H), 6.88 (t, J = 6.8 Hz, 1H), 2.51 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 181.6, 147.0, 145.8, 145.5, 142.2, 138.6, 138.5, 133.6, 133.4, 132.7, 132.4, 131.0, 130.7, 130.6, 128.5, 128.4, 128.3, 126.4, 125.8, 123.8, 122.2, 117.7, 113.2, 19.9; (IR, Neat): 3019, 1649, 1437, 1214, 746, 666 cm⁻¹; HRMS (ESI): Calculated for [C₂₇H₂₁ON₂S]⁺ 421.13691; Found 421.13397.

(E)-3-(4-fluorophenyl)-1-(5-(2-phenylimidazo[1,2-a]pyridin-3-yl)thiophen-2-yl)prop-2-en-1-one (3i)



Following the general procedure, the residue was purified by column chromatography (silica gel 60-120 mesh, 15% ethyl acetate in hexane as the eluent) to afford the title product as a yellow solid (0.189 g, 89%). M.p. 160-161 °C; ¹H NMR (300

MHz, CDCl₃) δ 8.21 (d, J = 6.9 Hz, 1H), 7.93 (d, J = 3.9 Hz, 1H), 7.85 (d, J = 15.5 Hz, 1H), 7.74 - 7.68 (m, 3H), 7.64 (dd, J = 8.6, 5.4 Hz, 2H), 7.39 - 7.30 (m, 5H), 7.24 (d, J = 3.9 Hz, 1H), 7.11 (t, J = 8.5 Hz, 2H), 6.86 (t, J = 6.8 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 181.4, 162.5, 146.9, 145.9, 145.6, 143.2, 138.6, 133.4, 132.4, 130.9, 130.7, 130.6, 130.5, 128.5, 128.3, 125.8, 123.8, 120.9, 117.8, 116.4, 116.1, 113.2; (IR, Neat): 3013, 1647, 1435, 1216, 748, 694 cm⁻¹; HRMS (ESI): Calculated for [C₂₆H₁₈ON₂SF]⁺ 425.11184; Found 425.10886.

(E)-3-(naphthalen-1-yl)-1-(5-(2-phenylimidazo[1,2-a]pyridin-3-yl)thiophen-2-yl)prop-2-en-1-one (3j)

Following the general procedure, the residue was purified by column chromatography (silica gel 60-120 mesh, 20% ethyl acetate in hexane as the eluent) to afford the title product as a yellow solid (0.207 g, 91%). M.p. 158-159 °C; ¹H NMR (300

MHz, CDCl₃) δ 8.75 (d, J = 15.3 Hz, 1H), 8.26 (dd, J = 15.5, 7.6 Hz, 2H), 7.97 – 7.88 (m, 4H), 7.75 – 7.69 (m, 3H), 7.62 – 7.51 (m, 4H), 7.40 – 7.29 (m, 4H), 7.26 (d, J = 1.3 Hz, 1H), 6.87 (td, J = 6.8, 1.0 Hz, 1H).; ¹³C NMR (75 MHz, CDCl₃) δ 181.5, 147.0, 145.9, 141.5, 138.7, 133.8, 133.4, 132.5, 132.0, 131.8, 131.1, 130.7, 128.8, 128.6, 128.5, 128.3, 127.1, 126.4, 125.8, 125.5, 125.2, 123.8, 123.7, 123.5, 117.8, 113.2; (IR, Neat): 3010, 1642, 1434, 1218, 749, 697 cm⁻¹; HRMS (ESI): Calculated for [C₃₀H₂₁ON₂S]⁺ 457.13691; Found 457.13362. Elemental Analysis: Calculated C, 78.92; H, 4.42; N, 6.14; S, 7.02; Found C, 79.28; H, 4.49; N, 5.34; S, 7.11.

(E)-1-(5-(2-(4-nitrophenyl)imidazo[1,2-a]pyridin-3-yl)thiophen-2-yl)-3-(p-tolyl)prop-2-en-1-one (3k)

Following the general procedure, the residue was purified by column chromatography (silica gel 60-120 mesh, 30% ethyl acetate in hexane as the eluent) to afford the title product as a yellow solid (0.211 g, 91%). M.p. 191-192 °C; ¹H NMR (300

MHz, CDCl₃) δ 8.29 (d, J = 8.8 Hz, 1H), 8.18 (d, J = 3.1 Hz, 2H), 8.11 (d, J = 8.8 Hz, 1H), 8.01 -7.97 (m, 2H), 7.91 (dd, J = 12.1, 3.3 Hz, 3H), 7.73 (d, J = 9.1 Hz, 1H), 7.57 (d, J = 8.0 Hz, 2H), 7.41 (d, J = 15.6 Hz, 1H), 7.31 (d, J = 10.2 Hz, 1H), 7.23 (d, J = 7.4 Hz, 1H), 6.92 (t, J = 6.4 Hz, 1H), 2.41 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 181.6, 148.4, 147.3, 146.1, 145.2, 141.7, 140.0, 136.8, 132.2, 131.8, 131.3, 129.8, 128.8, 128.7, 126.5, 126.4, 125.6, 124.2, 124.0, 123.8, 119.9, 118.0, 113.7, 113.2, 21.6; (IR, Neat): 3020, 1646, 1410, 1219, 750, 665 cm⁻¹; HRMS

(ESI): Calculated for $[C_{27}H_{20}O_3N_3S]^+$ 466.12199; Found 466.12190. Elemental Analysis: Calculated C, 69.66; H, 4.11; N, 9.03; S, 6.89; Found C, 70.18; H, 3.61; N, 8.78; S, 5.35.

(E)-3-(2,4-dimethoxyphenyl)-1-(5-(2-(4-nitrophenyl)imidazo[1,2-a]pyridin-3-yl)thiophen-2-yl)prop-2-en-1-one (3l)

Following the general procedure, the residue was purified by column chromatography (silica gel 60-120 mesh, 30% ethyl acetate in hexane as the eluent) to afford the title product as a yellow solid (0.222 g, 87%). M.p. 177-179 °C; ¹H NMR

(300 MHz, CDCl₃) δ 8.18 (dd, J = 13.4, 7.5 Hz, 3H), 8.10 (t, J = 13.8 Hz, 1H), 7.93 (t, J = 6.5 Hz, 3H), 7.72 (d, J = 8.9 Hz, 1H), 7.58 (d, J = 8.6 Hz, 1H), 7.50 (d, J = 15.6 Hz, 1H), 7.41 – 7.24 (m, 1H), 6.91 (t, J = 6.7 Hz, 1H), 6.55 (d, J = 8.6 Hz, 1H), 6.49 (d, J = 1.8 Hz, 3H), 3.93 (s, 3H), 3.87 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 182.2, 163.5, 160.8, 149.0, 147.3, 146.0, 142.6, 140.9, 140.1, 136.1, 131.8, 131.6, 131.3, 128.8, 126.5, 124.0, 123.8, 119.2, 118.0, 116.8, 114.7, 113.7, 105.6, 98.5, 55.6, 55.5; (IR, Neat): 2962, 1639, 1438, 1209, 744, 664 cm⁻¹; HRMS (ESI): Calculated for [C₂₈H₂₂O₅N₃S]⁺ 512.12747; Found 512.12627.

(*E*)-3-(2,4-dimethoxyphenyl)-1-(5-(2-(*p*-tolyl)imidazo[1,2-*a*]pyridin-3-yl)thiophen-2-yl)prop-2-en-1-one (3m)

Following the general procedure, the residue was purified by column chromatography (silica gel 60-120 mesh, 30% ethyl acetate in hexane as the eluent) to afford the title product as a yellow solid (0.211 g, 88%). M.p. 131-132 °C; ¹H NMR

(300 MHz, CDCl₃) δ 8.21 – 8.05 (m, 2H), 7.90 (d, J = 3.9 Hz, 1H), 7.69 (d, J = 9.0 Hz, 1H), 7.60 (dd, J = 12.7, 8.4 Hz, 3H), 7.49 (dd, J = 16.2, 3.3 Hz, 1H), 7.24 – 7.12 (m, 3H), 6.90 – 6.80 (m, 1H), 6.59 – 6.44 (m, 3H), 3.91 (d, J = 3.3 Hz, 3H), 3.86 (s, 3H), 2.36 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 182.3, 163.3, 160.7, 147.7, 145.7, 145.5, 140.4, 138.1, 137.8, 131.8, 131.5,

130.7, 130.6, 129.2, 128.3, 125.6, 123.8, 119.5, 117.6, 116.9, 113.0, 105.5, 98.5, 55.6, 55.5, 21.3; (IR, Neat): 2937, 1637, 1438, 1211, 749, 663 cm⁻¹; HRMS (ESI): Calculated for [C₂₇H₂₆O₃N₂S]⁺ 481.15563; Found 481.15627.

(E) - 1 - (5 - (2 - (p - tolyl)) imidazo [1, 2 - a] pyridin - 3 - yl) thiophen - 2 - yl) - 3 - (3, 4, 5 - a) - (3, 4, 5 - a)

trimethoxyphenyl)prop-2-en-1-one (3n)

Following the general procedure, the residue was purified by column chromatography (silica gel 60-120 mesh, 30% ethyl acetate in hexane as the eluent) to afford the title product as a yellow solid (0.214 g, 84%). M.p. 136-137 °C; ¹H NMR

(300 MHz, CDCl₃) δ 8.22 (d, J = 6.9 Hz, 1H), 7.97 (d, J = 3.9 Hz, 1H), 7.84 (d, J = 15.5 Hz, 1H), 7.76 – 7.69 (m, 1H), 7.65 – 7.60 (m, 1H), 7.36 – 7.29 (m, 2H), 7.19 (dd, J = 15.2, 9.5 Hz, 3H), 6.93 – 6.83 (m, 4H), 3.95 (s, 6H), 3.93 (s, 3H), 2.37 (s, 3H); 13 C NMR (75 MHz, CDCl₃) δ 189.7, 153.6, 147.1, 145.6, 144.8, 144.7, 140.8, 139.5, 138.2, 132.4, 131.8, 131.3, 130.6, 129.3, 128.3, 127.4, 125.7, 123.7, 120.4, 117.7, 113.1, 106.0, 61.0, 56.3, 21.3; (IR, Neat): 2937, 1642, 1413, 1242, 748, 664 cm⁻¹; HRMS (ESI): Calculated for [$C_{30}H_{27}O_4N_2S$]⁺ 511.16860; Found 511.16752.

(E)-1-(5-(6-methyl-2-phenylimidazo[1,2-a]pyridin-3-yl)thiophen-2-yl)-3-(p-tolyl)prop-2-en-1-one (30)

Following the general procedure, the residue was purified by column chromatography (silica gel 60-120 mesh, 15% ethyl acetate in hexane as the eluent) to afford the title product as a yellow solid (0.208 g, 96%). M.p. 148-149 °C; ¹H NMR (300

MHz, CDCl₃) δ 8.13 (d, J = 7.1 Hz, 1H), 7.93 (d, J = 4.0 Hz, 1H), 7.87 (s, 1H), 7.72 (dd, J = 7.8, 1.6 Hz, 2H), 7.58 (d, J = 8.1 Hz, 2H), 7.46 (d, J = 13.1 Hz, 2H), 7.39 – 7.34 (m, 3H), 7.25 (d, J = 8.0 Hz, 3H), 6.72 (dd, J = 7.1, 1.5 Hz, 1H), 2.46 (s, 3H), 2.42 (s, 3H); ¹³C NMR (75 MHz,

CDCl₃) δ 181.7, 146.8, 146.3, 144.6, 141.4, 138.7, 137.0, 135.8, 135.2, 133.6, 132.3, 131.9, 130.4, 129.8, 128.6, 128.5, 128.4, 128.1, 123.0, 120.1, 116.1, 115.8, 21.6, 21.4; (IR, Neat): 2926, 1643, 1435, 1213, 750, 665 cm⁻¹; HRMS (ESI): Calculated for [C₂₈H₂₃ON₂S]⁺ 435.15256; Found 435.15110.

(E)-3-(4-methoxyphenyl)-1-(5-(6-methyl-2-phenylimidazo[1,2-a]pyridin-3-yl)thiophen-2-yl)prop-2-en-1-one (3p)

Following the general procedure, the residue was purified by column chromatography (silica gel 60-120 mesh, 15% ethyl acetate in hexane as the eluent) to afford the title product as a yellow solid (0.211 g, 94%). M.p. 181-182

°C; ¹H NMR (300 MHz, CDCl₃) δ 8.13 (d, J = 7.0 Hz, 1H), 7.90 (t, J = 9.7 Hz, 2H), 7.76 – 7.70 (m, 2H), 7.64 (d, J = 8.7 Hz, 2H), 7.47 (s, 1H), 7.39 – 7.30 (m, 4H), 7.22 (d, J = 3.8 Hz, 1H), 6.96 (d, J = 8.7 Hz, 2H), 6.72 (d, J = 7.0 Hz, 1H), 3.88 (s, 3H), 2.46 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 181.6, 161.9, 147.0, 146.3, 145.3, 144.3, 138.4, 136.9, 133.6, 132.0, 130.4, 128.5, 128.4, 128.1, 127.3, 123.0, 118.8, 116.1, 115.7, 114.5, 55.5, 21.4; (IR, Neat): 2916, 1642, 1435, 1215, 748, 696 cm⁻¹; HRMS (ESI): Calculated for $[C_{28}H_{23}O_2N_2S]^+$ 451.14748; Found 451.14557. Elemental Analysis: Calculated C, 74.64; H, 4.92; N, 6.22; S, 7.12; Found C, 73.27; H, 4.84; N, 5.55; S, 6.96.

(*E*)-3-(2,4-dimethoxyphenyl)-1-(5-(6-methyl-2-phenylimidazo[1,2-*a*]pyridin-3-yl)thiophen-2-yl)prop-2-en-1-one (3q)

Following the general procedure, the residue was purified by column chromatography (silica gel 60-120 mesh, 20% ethyl acetate in hexane as the eluent) to afford the title product as a yellow solid (0.214 g, 89%). M.p. 121-123

°C; ¹H NMR (300 MHz, CDCl₃) δ 8.17 – 8.09 (m, 2H), 7.90 (d, J = 3.9 Hz, 1H), 7.73 (dd, J =

7.9, 1.5 Hz, 2H), 7.61 – 7.52 (m, 2H), 7.47 (s, 1H), 7.35 (q, J = 6.3 Hz, 3H), 7.21 (d, J = 3.9 Hz, 1H), 6.74 – 6.68 (m, 1H), 6.56 (dd, J = 8.6, 2.2 Hz, 1H), 6.50 (d, J = 2.2 Hz, 1H), 3.93 (s, 3H), 3.88 (s, 3H), 2.46 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 182.3, 163.3, 160.7, 147.5, 146.2, 145.2, 140.3, 137.9, 136.8, 133.7, 131.8, 131.4, 130.4, 128.4, 128.4, 128.0, 123.1, 119.6, 116.9, 116.1, 115.7, 113.5, 112.8, 105.5, 98.5, 55.6, 55.5, 21.4; (IR, Neat): 3019, 1643, 1439, 1214, 745, 667 cm⁻¹; HRMS (ESI): Calculated for [C₂₉H₂₅O₃N₂S]⁺ 481.15804; Found 481.15631.


(E)-1-(5-(6-methyl-2-phenylimidazo[1,2-a]pyridin-3-yl)thiophen-2-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (3r)


Following the general procedure, the residue was purified by column chromatography (silica gel 60-120 mesh, 30% ethyl acetate in hexane as the eluent) to afford the title product as a yellow solid (0.217 g, 85%). M.p. 158-159


°C; ¹H NMR (300 MHz, CDCl₃) δ 8.12 (d, J = 7.0 Hz, 1H), 7.94 (d, J = 3.9 Hz, 1H), 7.82 (d, J = 15.5 Hz, 1H), 7.71 (dd, J = 7.9, 1.7 Hz, 2H), 7.46 (s, 1H), 7.37 – 7.29 (m, 4H), 7.22 (d, J = 3.9 Hz, 1H), 6.88 (s, 2H), 6.71 (dd, J = 7.1, 1.6 Hz, 1H), 3.93 (s, 6H), 3.91 (s, 3H), 2.45 (s, 3H); 13 C NMR (75 MHz, CDCl₃) δ 181.4, 153.5, 146.6, 146.3, 145.4, 144.6, 140.8, 138.8, 136.9, 133.7, 132.3, 130.4, 130.1, 128.4, 128.1, 123.0, 120.4, 116.2, 115.7, 112.6, 105.9, 61.0, 56.3, 21.4; (IR, Neat): 3011, 1644, 1417, 1217, 746, 696 cm⁻¹; HRMS (ESI): Calculated for [C₃₀H₂₇O₄N₂S]⁺ 511.16860; Found 511.16752. Elemental Analysis: Calculated C, 70.57; H, 5.13; N, 5.49; S, 6.28; Found C, 69.54; H, 5.21; N, 4.13; S, 5.53.


1.4 References


- 1. K. S. Gudmundsson and B. A. Johns, *Bioorg. Med. Chem. Lett.* **2007**, *17*, 2735–2739.
- 2. B. Ramesh, and B. Someswara Rao, E-Journal of Chemistry, 2010, 7, 433-436.








































18171 1440 1440 1418 39 1133 48 1133 48 1122 38 1123 81 1123 81 1123 81 1123 81 1123 81 113 82 113 82 113 82 113 82 113 82 113 83 113 83 113 83 113 83 113 83 113 83 113 83 113 83 113 83 113 83 113 83 113 83 113 83 113 83 114 83 115 83 117 83 118 83 11

































1.46 3.9 1.45 3











163 47 160 347 140 031 140


























1817 166.88 167.88 66 173.86 68 173.86 68 173.87 78 86 173.87 78 86 173.88 66 17


77.48


C21.63














1 182.2 1 19.

